The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.

Inclusion Criteria:

• Male and female patients 12 years and older with a compatible history greater than or equal to 1 year of rhinitis due to perennial allergies.
• Must be willing and able to provide informed consent and to participate in all study procedures
• Must be in generally good health
• Positive skin test to a prevalent perennial allergen

Exclusion Criteria:

• On nasal examination, the presence of nasal mucosal erosion, nasal ulceration or nasal septal perforation
• Use of any investigational drug within 30 days of the first visit
• Any nasal surgery or sinus surgery within the previous year
• Presence of any hypersensitivity to drugs similar to azelastine or mometasone furoate and to either sorbital or sucralose
• Women who are pregnant or nursing
• Women who are not using an acceptable method of birth control
• Nasal Diseases likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa or clinically significant nasal polyposis or nasal structural abnormalities.
• Asthma or other lung diseases such as COPD. Mild asthma symptoms may be considered after consultation with investigator.
• Patients with Arrythmia
• Patients with know history of alcohol and drug abuse
• Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor, might significantly alter the evaluation of the study.
• Use of medications that could affect the study results